524 results about "Purine" patented technology

The invention relates to the technical field of agricultural science, and discloses a low-purine ecological pig circulating breeding system which comprises a breeding environment regulation and control module, a low-purine feed management module, an excrement treatment module, a recycling module, a health monitoring module, an intelligent decision-making module, a traceability management module, a water quality purification module and an energy recovery module. The breeding environment regulation and control module monitors in real time and automatically regulates pig house environment parameters through a distributed sensor network; the low-purine feed management module generates a low-purine feed formula based on growth stage recognition and nutritional requirement analysis; the excrement treatment module is used for converting breeding wastes into organic fertilizer raw materials; the cyclic utilization module realizes precise returning of the organic fertilizer to the field according to planting requirements; the health monitoring module evaluates the purine level of the swinery; the intelligent decision-making module integrates the multi-source data to generate a comprehensive optimization scheme; and the traceability management module records whole-process data through a block chain technology. The stability of low-purine culture is guaranteed, and the success rate of low-purine culture is increased.

The present invention discloses the application of a 1,7-dihydro-6H-purin-6-one compound in the preparation of an anti-pulmonary fibrosis drug, which relates to the technical field of biomedicine. The application of the 1,7-dihydro-6H-purin-6-one compound of the present invention in the preparation of an anti-pulmonary fibrosis drug detects the anti-pulmonary fibrosis pharmacological activity of the 1,7-dihydro-6H-purin-6-one compound after structural modification and transformation, tests the pharmacological activity of this type of compound in a variety of animal disease models, and provides data on the activity of preventing and treating different types of pulmonary fibrosis, confirming that they all have good activity, and the effect is significantly better than the clinically commonly used positive drug nintedanib, and the effect is also better than hypoxanthine analogs A, B, and C. The application of the 1,7-dihydro-6H-purin-6-one compound of the present invention in the preparation of an anti-pulmonary fibrosis drug can provide a new skeleton for the screening of new compounds for the preparation of anti-pulmonary fibrosis drugs, and lay a theoretical foundation for the development of new lead compounds.

The present invention provides a compound of Formula (I):or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by nuclear SET domain-containing protein 2 (NSD2).

The invention provides a perovskite solar cell, a preparation method thereof and a photovoltaic module. The perovskite solar cell comprises a first electrode, a hole transport layer, a perovskite layer, an electron transport layer and a second electrode which are stacked in sequence. The material of the hole transport layer comprises a biomolecular material which is fixed on a self-assembly monomolecular layer material through an intermolecular force, and the biomolecular material comprises one or more of guanine, adenine, thymine, uracil, cytosine, hydroxymethylcytosine, xanthine, hypoxanthine, 6-mercaptopurine and corrin. According to the perovskite cell provided by the invention, the biomolecular material with a plurality of nitrogen heterocyclic structures and amino groups is added to generate multipoint hydrogen-bond interaction and pi-pi accumulation with the tail end of the SAM, so that the orderliness of molecular arrangement is improved, and the dipole direction and strength of the whole interface are regulated and controlled; and a coordination bond or hydrogen bond network is formed by the coordination compound and uncoordinated cations or anions in perovskite, so that interface defects are effectively passivated, and the thermal stability and the humid and hot life of a device are enhanced.

The invention provides a strain of fermentation lactobacillus mucus TG017, and the strain of fermentation lactobacillus mucus TG017 has the effects of reducing uric acid, purine and adenosine. The lactobacillus fermentum is lactobacillus fermentum TG017, is preserved in the China Center for Type Culture Collection on April 10, 2023, has the preservation number of CCTCC NO: M 2023513, and is located in the preservation center of Wuhan University in Hubei China, and the preservation number of the lactobacillus fermentum TG017 is CCTCC NO: M 2023513. The invention further relates to the use of the Lactobacillus mucilaginosus TG017 strain.

The invention relates to the field of microorganisms, and discloses a Lactococcus lactis subsp. Lactis VB346 which is preserved in the China Center for Type Culture Collection on September 20, 2024, and the preservation number is CCTCC NO: M 20242013. The invention further discloses a preparation method of the Lactococcus lactis subsp. Lactis VB346. The lactococcus lactis subsp. Lactis VB346 disclosed by the invention has the capability of efficiently degrading purine nucleoside, and can decompose purine nucleoside in ingested food in intestinal tracts, so that the absorption amount of purine nucleoside by small intestines is reduced. The polypeptide has the ability of degrading bilirubin, and can be used for treating or improving hyperbilirubinemia, or improving liver and gall injury caused by hyperbilirubin; meanwhile, the acid resistance required by survival in the stomach, the cholate tolerance required by survival in the intestinal tract and the stable survival ability in the intestinal tract are achieved, and the bacillus subtilis has huge application prospects in preparation of drugs, microbial agents, health care products or food.

The invention relates to application of plant lactobacillus FBL002 in degradation of purine nucleoside, and belongs to the technical field of microorganisms. The plant lactobacillus FBL002 provided by the invention is preserved in Guangdong Microbial Culture Collection Center on March 13, 2025, and the preservation number is GDMCC No.66015. The strain is separated from healthy infant intestinal flora, and can effectively degrade various purine nucleosides including inosine, guanosine, adenosine, guanine and adenine, so that the plant lactobacillus FBL002 is used for developing products for degrading purine nucleosides. In addition, the strain is also suitable for preparing oral hyperuricemia treatment medicines, and the contents of uric acid, xanthine oxidase and adenosine deaminase in serum can be remarkably reduced. The invention provides a safe and efficient method for managing purine metabolism abnormality related diseases by utilizing the biodegradation activity of the plant lactobacillus FBL002, and is particularly suitable for preventing and treating hyperuricemia.

The invention relates to the fields of biology, medicine and clinic. In particular to application of PAICS as a target spot in developing or screening reagents for preventing and / or treating orthopoxvirus infection, and application of inhibiting a synthetic pathway of purine nucleotide and / or inhibiting a metabolic pathway of folic acid in preparing reagents for treating and / or preventing orthopoxvirus infection diseases. In order to restrain the infection of orthopoxvirus, the inventor team uses a CRISPR / Cas9 technology to carry out generic genome screening on host cells infected by orthopoxvirus, determines a host-dependent gene PAICS gene in the orthopoxvirus infection process, and verifies and clarifies the virus-dependent mechanism of the gene; in order to deal with the global continuous orthopoxvirus infection problem, the invention plays an important role in the development and screening of future related prevention or treatment drugs, and also expands the new clinical application of existing drugs including methotrexate, mercaptopurine, mizoribine and the like.

The invention belongs to the technical field of sensors, and relates to an array sensor based on cerium-based metal organic framework nano-enzyme and detection application of perfluoroalkyl compounds. The array sensor is a Ce-MOF triple enzyme activity array sensor and is provided with a plurality of mutually independent sensing channels; the sensing channel contains a Ce-MOF nano enzyme and a chromogenic substrate; the chromogenic substrates comprise a first chromogenic substrate, a second chromogenic substrate and a third chromogenic substrate, the first chromogenic substrate comprises 3, 3 ', 5, 5'-tetramethyl benzidine, the second chromogenic substrate comprises 2, 4-diaminophenol and 4-aminoantipyrine, and the third chromogenic substrate comprises xanthine, purine oxidase and nitrogen blue tetrazole. The MOF nano-enzyme array sensor constructed by the invention has relatively high sensitivity and selectivity in identification and distinguishing of PFASs compounds, not only can accurately distinguish single PFASs compounds, but also can perform quantitative detection, and has good response to PFASs with different concentrations.

The invention discloses targeted prebiotic plant extraction dietary powder for relieving hyperuricemia and a preparation technology of the targeted prebiotic plant extraction dietary powder, and belongs to the technical field of dietary powder.In a formula of the targeted prebiotic plant extraction dietary powder for relieving hyperuricemia, as a patented bacterial strain, the bacillus coagulans MKSWC01 can directly act on the intestinal tract environment, uric acid precursor substances generated by purine metabolism are degraded in a targeted mode, and generation of uric acid is reduced from the source; the chicory root superfine powder and the mulberry leaf DNJ extract respectively activate kidney excretion protein, inhibit the activity of glycosidase, accelerate discharge of uric acid through urine and block the path of conversion from fructose metabolism to uric acid; the celery seed flavone and the smilax glabra polysaccharide further play an anti-inflammatory role, the deposition risk of urate crystals at joints is reduced, and potential inflammatory response caused by hyperuricemia is relieved. Meanwhile, the resistant dextrin and the xylooligosaccharide serve as prebiotics, nutrients are provided for probiotics to support planting of the probiotics, the overall metabolic environment can be improved by adjusting intestinal flora balance, the pathological link of hyperuricemia is comprehensively covered, and the relieving effect is improved.

A compound of the structure:or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

The invention provides deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, pharmaceutical compositions, their use in inhibiting NSD2, and their use in the treatment of a disease or condition, such as cancer.

The invention provides a method for preparing low-purine beer based on high-energy fluid mill equipment, and relates to the field of beer. Comprising the following steps: preparing clarified wort, and pumping the clarified wort into a high-energy fluid mill for treatment to obtain treated wort; the treated wort is subjected to flavor treatment and fermentation treatment, and the low-purine beer is obtained. The method is mainly based on a high-density energy input physical method, purine combined in nucleic acid in wort can be effectively released and is converted into a free state, the utilization rate of purine is increased through fermentation proliferation of yeast, and the purpose of reducing the purine content in a beer product is achieved. The production process flow is simple, the purine reduction effect is obvious, and the prepared beer is excellent in sense, rich in taste level, suitable for industrial production and wide in application prospect.

The invention relates to the field of medicinal chemistry, and particularly discloses purine compounds as well as a preparation method and application thereof. The purine compound provided by the invention is a compound as shown in a formula (I) or pharmaceutically acceptable salt thereof: # imgabs0 #. The purine compound disclosed by the invention is designed based on a novel purine skeleton structure, and the anti-herpes simplex virus type 1 (HSV-1) activity of the purine compound is verified through an in-vitro antiviral experiment. Experimental data show that the HSV-1 median inhibitory concentration (EC50) of the series of compounds to HSV-1 is obviously superior to that of a clinical first-line drug acyclovir, and the series of compounds show better virus inhibition efficiency on the premise of keeping a similar selectivity index (SI = CC50 / EC50). The technical scheme breaks through the molecular framework limitation of the existing anti-HSV-1 drugs (such as acyclovir, famciclovir and the like), and has good clinical transformation value.

The purpose of the present invention is to provide a novel beer-flavored fermented beverage in which the purine concentration is reduced and the deterioration in flavor due to the reduction in purine concentration is improved. The present invention provides a beer-flavored fermented beverage having a purine concentration of 35,000 ppb or less, an adenosine concentration of 15,000 ppb or less, or a guanosine concentration of 56,000 ppb or less, wherein the 5-methylfurfural concentration is 10 ppb or more.

The invention belongs to the technical field of detection, and particularly relates to an orderly layered SERS (Surface Enhanced Raman Scattering) detection membrane as well as a preparation method and application thereof to detection of purine needling effect substances. The preparation method of the SERS detection membrane comprises the following steps: preparing noble metal nano-sol with different particle sizes, wherein the surface of the noble metal nano-sol is modified with a hydrophilic stabilizer; the preparation method comprises the following steps: respectively dispersing precious metal nano-sol with different particle sizes into water, then adding dispersion liquid, and after shaking, spontaneously assembling nano-particles on a gas-liquid interface to form a single-layer nano-particle film; the method comprises the following steps: transferring a nano-particle film to the surface of a flexible film, drying, transferring nano-particle films with at least two particle sizes on the surface of the nano-particle film, and drying to obtain the SERS detection film loaded with at least three layers of nano-particle films with different particle sizes, wherein the particle sizes of the nanoparticle films are sequentially reduced from outside to inside. According to the SERS detection membrane, macromolecular protein and small molecular purine in acupuncture body fluid can be separated out, and high-sensitivity and high-stability detection on the macromolecular protein and the small molecular purine can be achieved on the front face and the back face of the SERS detection membrane respectively.

The invention belongs to the technical field of medicines, and discloses an application of a small molecule compound in preparation of a product for preventing and / or treating pulmonary arterial hypertension and complications thereof. The small molecule compound is 8-[[4-(cyclopropanecarbonyl) piperazine-1-yl] methyl]-1, 3-dimethyl-7-(3-methylbutyl) purine-2, 6-diketone, and the structural formula is as shown in a formula (I): # imgabs0. The small molecule compound and pharmaceutically acceptable salts thereof have a remarkable treatment effect on pulmonary arterial hypertension and complications thereof, and can be used for treating pulmonary arterial hypertension and complications thereof. The effects of preventing and / or treating the pulmonary arterial hypertension include the reduction of right heart hypertrophy, the reduction of right ventricular systolic pressure, right heart enlargement, right heart dysfunction, pulmonary vascular remodeling, pulmonary arterial intima thickness, increase of vascular myelization, pulmonary arterial smooth muscle cell proliferation and migration, the reduction of the right ventricular hypertrophy, the reduction of the right ventricular hypertrophy, the reduction of the right ventricular hypertrophy and the reduction of the right ventricular hypertrophy. The pulmonary arterial intima thickness and the vascular myelization level are improved, pulmonary vascular remodeling is reversed, and pulmonary artery smooth muscle cell proliferation and migration are inhibited.

The present invention provides a method for producing ribose-1-phosphate that is simple and yields improved efficiency. [Solution] A method for producing ribose-1-phosphate, comprising a contact step to produce ribose-1-phosphate and hypoxanthine by contacting inosine, a phosphate donor, an enzyme having purine nucleoside phosphorylase activity, and a medium in a reaction solution containing inosine, a phosphate donor, an enzyme having purine nucleoside phosphorylase activity, and a medium, wherein in the contact step, the hypoxanthine is present in an amount exceeding the saturation concentration relative to the medium.

The present application relates to a kind of purine derivatives as the use of NSD2 and NSD3 inhibitor, the structural formula of the derivative is as shown in formula (I) or formula (II).The compound shows good NSD2, NSD3 inhibitory activity, can effectively reduce the methylation level of H3K36 in cell, and cause the reduction of cell proliferation activity of NSD2, NSD3 high expression tumor cell strain.

The invention provides deuterium-enriched piperidinyl-methyl-purine amines and related compounds, pharmaceutical compositions, their use for inhibiting NSD2, and their use in the treatment of a disease or condition, such as cancer.

The invention relates to lactobacillus mucilaginosus and application thereof in fermented soybean milk. The lactobacillus mucus is preserved in the Guangdong Microbial Culture Collection Center on March 10, 2025, and the preservation number is GDMCC (China General Microbiological Culture Collection Center) No. 65866. The viable count of the fermented lactobacillus mucus in soybean milk is increased by 56%, meanwhile, the activity of beta-glucosidase is remarkably improved to 198 U / mL, and the degradation rate of total purine in soybean milk is 65.32%. In fermentation application, the total polyphenol content and the total flavone content in fermented soybean milk after fermentation are respectively increased by 39.56% and 52.32% compared with those in an unfermented system, the daidzein content and the genistein content in the fermented soybean milk after fermentation are respectively increased by 256.3% and 356.3% compared with those in the unfermented system, and meanwhile, the antioxidant activity ABTS free radical scavenging rate and the antioxidant activity DPPH scavenging rate are obviously increased to 89.6% and 94.8% respectively. The strain shows important application value in the fields of functional food development and natural cosmetic raw material production, and an innovative solution is provided for high-value utilization of plant resources.

The invention provides deuterium-enriched piperidinyl-methyl-purine amines and related compounds, pharmaceutical compositions, their use for inhibiting NSD2, and their use in the treatment of a disease or condition, such as cancer.

The invention provides deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, pharmaceutical compositions, their use in inhibiting NSD2, and their use in the treatment of a disease or condition, such as cancer.

The invention provides deuterated aza-adenine and a preparation method and application thereof.The deuterated aza-adenine has the structure shown in the formula (I), the deuterated aza-adenine compound can improve the molecular stability, the copper surface binding force of a product is improved when the deuterated aza-adenine compound is applied to a photosensitive composition, and the yield of the product is improved. And other application performances of the molecules are not influenced.

The invention provides application of a roxburgh rose extract in preparation of a product for treating hyperuricemia and regulation and control of a purine metabolic pathway, and belongs to the technical field of biological medicines. The roxburgh rose aqueous extract extracted from roxburgh rose pomace can effectively intervene in hyperuricemia through a dual action mechanism: on one hand, the roxburgh rose aqueous extract significantly inhibits the expression of xanthine oxidase (XOD) in the liver, and reduces the generation of uric acid; on the other hand, expression of key urate transporters (including GLUT9, URAT1, ABCG2 and OAT1) is regulated and controlled, uric acid is promoted to be excreted through the kidney, and therefore the blood uric acid level is reduced in a synergistic mode, a solid theoretical basis and technical support are provided for developing a new HUA prevention and treatment strategy based on natural products, and a new thought is provided for prevention and treatment of hyperuricemia.

This document provides methods and materials for manipulating telomere length. For example, this document provides methods and materials for using one or more agents that can manipulate (e.g., increase or decrease) telomere length. In some cases, one or more agents that can increase telomere length can be contacted with a cell to increase telomere length in that cell. For example, one or more agents that can increase telomere length can be administered to a mammal having one or more TBDs to increase telomere length in cells within the mammal (e.g., to treat the mammal). In some cases, one or more agents that can decrease telomere length can be contacted with a cell to decrease telomere length in that cell. For example, one or more agents that can decrease telomere length can be administered to a mammal having a disease or disorder associated with increased telomere synthesis and / or increased telomerase activity to decrease telomere length in cells within the mammal (e.g., to treat the mammal).

The invention relates to lactobacillus reuteri SAU-R-8 which is derived from Tibet naturally-fermented sour yak milk and is used for producing exopolysaccharides and application of the lactobacillus reuteri SAU-R-8 in reducing uric acid, and belongs to the technical field of microorganisms. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30373, and the preservation date is April 19, 2024. The lactobacillus reuteri SAU-R-8 provided by the invention is screened from yak yogurt naturally fermented from herdsmen in the Sankarst region of Tibet, the yield of exopolysaccharides in an MRS culture medium reaches 318.57 mg / L, nucleoside substances such as inosine and guanosine can be efficiently degraded, purine substances such as guanine can be efficiently absorbed, the activity of xanthine oxidase can be inhibited, and the lactobacillus reuteri SAU-R-8 can be used for preparing the yak yogurt. The method can be further applied to product development for relieving or treating hyperuricemia.

The invention provides a plasmid for purine base mutation in blue-green algae and a preparation method and application thereof, and belongs to the field of bioengineering, the plasmid provided by the invention is named as pCyABE, the plasmid comprises a TadA-nCas9 fusion protein expression cassette and an sgRNA expression cassette, the nucleotide sequence of the TadA-nCas9 fusion protein expression cassette is shown as SEQ ID No.2, the nucleotide sequence of the sgRNA expression cassette is shown as SEQ ID No.2, and the nucleotide sequence of the sgRNA expression cassette is shown as SEQ ID No.2. The nucleotide sequence of the sgRNA expression cassette is as shown in SEQ ID No. 3. The plasmid provided by the invention is particularly suitable for mutation of adenine at any site on a blue-green algae genome into guanine, realizes fixed-point editing of the gene, has the advantages of high editing efficiency and low off-target rate, and has important significance on physiological property research and industrial application of blue-green algae.

The invention discloses a construction and verification method of an HEK293T cell line capable of stably overexpressing human ANT2, which comprises the following steps: cloning a human ANT2 gene, constructing the human ANT2 gene into a lentivirus expression plasmid pLVX-TRE3G, co-transfecting the lentivirus expression plasmid pLVX-TRE3G and a helper plasmid pLVX-Tet3G into an HEK293T-ACE2 cell, and carrying out puromycin and G418 pressurized screening and Western blot identification to obtain the HEK293T cell line capable of stably overexpressing human ANT2. A result shows that the expression quantity of the ANT2 is the highest when the HEK293T-ACE2-ANT2 cell is induced for 12 hours at the Doxycycline of 6mg / L; when the ANT2 is induced to express, the virus nucleic acid load and the N protein expression level after SARS-CoV-2 infection are obviously reduced, which indicates that the ANT2 has an inhibition effect on SARS-CoV-2 infection replication, and a cell model and an experimental basis are provided for exploring the effect of the ANT2 in virus infection resistance.

Novel and known substituted purine compounds and salts thereof act as adenosine A2a receptor (A2aR) antagonists for cancer immunotherapy, depression, anxiety, multiple sclerosis, NASH, scleroderma, ADHD, Alzheimer's and Parkinsons. Pharmaceutical compositions comprising such compounds, and methods of their use in treating depression are also taught.